Cefquinome is a new injectable aminothiazolyl cephalosporin derivative. It is stable against chromosomally and plasmid-encoded I8-lactamases and has a broad antibacterial spectrum. Staphylococcus aureus, streptococci, Pseudomonas aeruginosa, and members of the family Enterobacteriaceae (Escherichia coli, Salmonella spp., Klebsiella spp., Enterobacter spp., Citrobacter spp., and Serratia marcescens) are inhibited at low concentrations. Cefquinome is also active against many strains of methicillin-resistant staphylococci and enterococci. Its in vitro activity against gram-negative anaerobes is very limited. The high in vitro activity of cefquinome is reflected by its high in vivo efficacy against experimental septicemia due to different gram-positive and gram-negative bacteria. We studied the pharmacokinetic properties of cefquinome in mice, dogs, pigs, and calves. After single parenteral administrations, cefquinome displayed high peak levels, declining with half-lives of about 0.5, 0.9, 1.2, and 1.3 h, respectively. The areas under the concentration-time curve determined for dogs and mice showed linear correlations to the given doses. In dogs the urinary recovery was more than 70% within 24 h of dosing.
At present cephalosporins are widely used for the treatment of infections in humans. The aminothiazolyl cephalosporins are particularly important because they possess favorable chemotherapeutic properties and are associated with low rates of adverse effects (1, 8) . Cefotaxime was the first representative of this group of cephalosporins (11) . During our efforts to find new derivatives with even broader antibacterial spectra or better pharmacokinetics, a series of polar cephalosporins was synthesized (3) . From these compounds, cefpirome was selected to be developed for use in human medicine (6, 13) .
Cefquinome (HR 111V) ( Fig. 1 ) is another representative of this group. Here we report the antibacterial activity of cefquinome in vitro, its therapeutic efficacy in experimental infections, and its pharmacokinetic properties in animals.
(This work was presented in part at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Tex., 1989, abstr. no. 479 and 480.)
MATERIALS AND METHODS
Antimicrobial agents. Cefquinome, cefotaxime, and cefpirome were synthesized by Hoechst AG, Frankfurt, Federal Republic of Germany. Cefoperazone and cefuroxime are commercially available.
Bacterial strains. The bacterial strains used were clinical isolates obtained from various hospitals in Europe between 1978 and 1988 and strains maintained in our own laboratories. All bacterial strains were stored on agar slants at room temperature or as suspensions in liquid nitrogen.
Antimicrobial susceptibility testing. The susceptibility of aerobic bacteria was tested by means of the agar dilution test on Mueller-Hinton agar (Difco, Detroit, Mich.). When streptococci were tested, the agar was supplemented with 10% horse blood. Plates were inoculated with a multipoint inoculator (Greiner, Nuirtingen, Federal Republic of Germany) which delivered 5 x 104 CFU per spot of stationary, freshly * Corresponding author. diluted cultures of the strains concerned. The MIC was taken as the lowest concentration at which no visible growth could be detected after 24 h at 37°C. The MICs for methicillin-resistant Staphylococcus aureus were read after 48 h at 30°C. The MICs for 50 and 90% of the isolates (MlC50 and MIC90, respectively) were calculated from the results.
The susceptibility of obligate gram-positive and gramnegative anaerobes was tested by using the agar dilution test on Wilkins-Chalgren agar (Oxoid, Wesel, Federal Republic of Germany). Overnight cultures of the appropriate test strains diluted 1:10 in fresh thioglycolate medium (Oxoid) were used as the inoculum. The MICs of the antibiotics were determined after the plates had been incubated in anaerobic jars (Oxoid) for 48 h at 37°C.
f8-Lactamase stability. The enzymes used were released from the bacteria by ultrasonication and partially purified by chromatography on Sephacryl S-200 superfine (Pharmacia, Freiburg, Federal Republic of Germany). For the spectrophotometric UV test (11), 2 ml of a 10' M solution of cefquinome and 50 ,ul of enzyme solution were mixed. The A255 was monitored for 10 min at room temperature. The relative rates of hydrolysis were compared with the decay of cephaloridine.
Affinity to PBPs. The binding of cefquinome to penicillinbinding proteins (PBPs) of Escherichia coli K-12 was determined as previously described (12) by using 125I-ampicillin.
Influence of nutrient medium. The effect of the composition of the culture medium was examined in the serial macrodilution test. Geometrical dilution series of the compound were prepared in different fluid nutrient media and inoculated with suspensions of the test organisms. The following commercial bacterial culture media were used:
Mueller-Hinton medium (Difco), ABM III (Difco), standard I (Merck), heart infusion medium (Difco), brain heart infusion medium (Difco), standard bouillon (Oxoid), 1% Tryptone (Difco), Iso-Sensitest broth (Oxoid), and nutrient broth (Oxoid). Tables 1 and 2 . The data indicate that cefquinome has high antibacterial activity in vitro against nearly all strains tested. The MICs of cefquinome (Table 1) for methicillin-susceptible and methicillin-resistant staphylococci are nearly identical to those of cefpirome, i.e., in the range of 0.195 to 50 pug/ml. Thus, the MIC50s and MIC90s of cefquinome (1.563 and 25 ,ug/ml, respectively) are slightly lower than those of cefotaxime.
The MIC90 of cefquinome against streptococci of serogroups A, B, and C is 0.024 ,ug/ml and is therefore slightly lower than that of cefpirome and cefotaxime. Against enterococci the MIC90 of cefquinome was about 32 ,ug/ml, indicating that against this group of bacteria cefquinome is slightly more active than cefpirome but significantly more active than cefotaxime.
All the species of the Enterobacteriaceae tested are usu- Effect of medium composition and pH on in vitro activity. The MICs of cefquinome for S. aureus SG 511 and E. coli 1507E in nine commercial culture media (Mueller-Hinton medium, ABM III, standard I, heart infusion medium, brain heart infusion medium, standard bouillon, 1% Tryptone, Iso-Sensitest, and nutrient broth 2) were determined. The MICs of the compound for S. aureus SG 511 and E. coli 1507E varied only by one dilution step (0.313 to 0.625 and 0.062 to 0.125 ,ug/ml, respectively). Thus, the antibacterial activity of cefquinome does not depend upon the composition of the culture medium. The antibacterial activity of cefquinome for the same test organisms does not vary markedly in Mueller-Hinton medium adjusted to pH values ranging from 5.5 to 9.0.
In vivo efficacy in mouse septicemia. The high in vitro activity of cefquinome (Table 3 ) against the pathogens involved was reflected by excellent in vivo activity against the septicemias induced in mice by these strains. Cefquinome has good in vivo activity against S. aureus, which is not typical for most other broad-spectrum cephalosporins including cefotaxime. Table 3 clearly demonstrates that cefquinome is superior to cefotaxime, cefoperazone, and cefuroxime as regards protection against the experimental S. aureus Giorgio and SG 511 infections in mice. The ED50s of cefquinome for these strains are 0.96 and 1.6 mg/kg, respectively, which is 6 to 12 times more active than the reference compounds. The activity demonstrated by cefquinome against infections due to Streptococcus pyogenes A77 was also higher than that of cefotaxime, cefoperazone, and cefuroxime. The Streptococcus pneumoniae infection also responded well to cefquinome. The ED50 (0.17 mg/kg) of cefquinome was 2 to 15 times lower than those of the reference compounds.
In addition, Table 3 elimination half-lives in dogs (Table 5) , pigs (Table 6) , and calves ( (Table 4 ) and in dogs (Table 5 ) about 80% and 63 to 78%, respectively, of the dose was recovered in the urine as antibacterially active substance within 24 h of administration.
DISCUSSION
The introduction of a methoxyimino-aminothiazolyl moiety in the acyl side chain of cephalosporins brought about significant enhancement of activity, extension of the antibacterial spectrum-especially against gram-negative bacteria-and high resistance to inactivation by P-lactamases (3, 9) . The introduction of polar C-3'-substituents into a cephem nucleus improves the activity of the aminothiazolyl cephalosporins, especially against staphylococci and P. aeruginosa, without loss of activity against members of the Enterobacteriaceae. Cefquinome is a representative of this group of cephalosporins, as are cefpirome (5) and cefepime (2) . The results of our investigations proved that cefquinome has a broad spectrum of activity. The spectrum includes staphylococci, streptococci, and many strains of methicillin-resistant staphylococci and enterococci. The most important members of the Enterobacteriaceae (E. coli, Klebsiella spp., Salmonella spp., Citrobacter spp., Enterobacter spp., and Proteus spp.) are inhibited at low concentrations. Most strains ofP. aeruginosa are also susceptible to cefquinome. Owing to its resistance to various plasmid-encoded or chromosomally encoded P-lactamases, cefquinome is also active against bacteria that are resistant to earlier cephalosporins. Its action against gramnegative strict anaerobic bacteria (e.g., Bacteroidesfragilis) is limited, as is that of cefpirome and cefepime (2, 4) .
The in vitro activity of cefquinome, similarly to those of other cephalosporins, does not depend on the composition or pH of the test medium.
The broad antibacterial spectrum and the high in vitro activity of cefquinome are reflected by high in vivo efficacy in experimental infections. In mouse models of septicemia induced by both gram-positive and gram-negative bacteria, cefquinome possessed high therapeutic efficacy. All infections were cured by the administration of cefquinome. The ED50s were usually below 1 mg/kg.
The pharmacokinetic properties of cefquinome make a major contribution to its high in vivo activity. After parenteral administration to mice, dogs, pigs, or calves, high and sustained levels were measured in blood. The elimination half-lives are comparable to those of other polar cephalosporins. Cefquinome is excreted mainly by the kidneys: within 24 h of administration, 60 and 80% of the administered dose was recovered in the urine of mice and dogs, respectively.
In conclusion, cefquinome is a new representative of the polar aminothiazolyl cephalosporins. With its broad antibacterial spectrum and favorable pharmacokinetics, it merits further investigation into its chemotherapeutic properties.
